Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study

Published:2019-01 Issue:1 Volume:41 Page:59-67
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Okada Naoto,Kawazoe Hitoshi^ORCID,Takechi Kenshi,Matsudate Yoshihiro,Utsunomiya Ryo,Zamami Yoshito^ORCID,Goda Mitsuhiro,Imanishi Masaki,Chuma Masayuki,Hidaka Noriaki,Sayama Koji,Kubo Yoshiaki,Tanaka Akihiro,Ishizawa Keisuke

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs;Wong;Int Immunol,2007

2. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer;Hellmann;Cancer Cell,2018

5. Mutational heterogeneity in cancer and the search for new cancer-associated genes;Lawrence;Nature,2013

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma;Cancer Medicine;2024-06

2. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?;Frontiers in Immunology;2024-05-10

3. Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer;Molecular and Clinical Oncology;2024-02-20

4. Clonal redemption of B cells in cancer;Frontiers in Immunology;2023-10-26

5. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis;International Journal of Clinical Oncology;2023-09-02